CSBRChampions Oncology
About Champions Oncology
Champions Oncology (NASDAQ:CSBR) specializes in developing advanced technology solutions and services to personalize the development and use of oncology drugs. As the company focuses on translational oncology research, Champions Oncology leverages its proprietary TumorGraft platform – a novel approach that involves transplanting human tumors into immunodeficient mice – to guide the development of therapeutic and diagnostic solutions for cancer patients. Operating with the objective to enhance drug development through precise models that mimic human cancer environments, Champions Oncology's work spans preclinical mouse models to phase II/III clinical trials, aiming to improve outcomes for cancer patients by identifying the most effective cancer treatments.
What is CSBR known for?
Snapshot
Public US
Ownership
1985
Year founded
230
Employees
Hackensack, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Champions Oncology
- Translational oncology solutions linking laboratory findings with clinical trial outcomes.
- Personalized oncology services offering tailored treatment plans.
- Preclinical mouse models for cancer research and drug development.
- Comprehensive tumor profiling services for complex cancer cases.
- Pharmacology and toxicology studies to support drug approval processes.
- Bioinformatics services, analyzing complex data for drug discovery and development.
equipe executiva do Champions Oncology
- Dr. Ronnie Morris M.D.Executive Chair
- Mr. Robert BraininCEO & Director
- Mr. David Barry Miller M.B.A.Chief Financial Officer
- Dr. Maria Mancini Ph.D.Chief Operating Officer
- Dr. Marianna Zipeto Ph.D.Executive Vice President of Commercial, Research Services & Partnering